Merck Stands Behind the Safety Profile of JANUVIA® (sitagliptin)
WHITEHOUSE STATION, N.J., March 14, 2013 – Merck, known as MSD outside the United States and Canada, today issued the following statement in response to a communication from the U.S. Food and Drug...
View ArticleMerck Provides Update on Combination Medicine JUVISYNC™ (sitagliptin and...
News Organization: Merck News Organization Location: WHITEHOUSE STATION, N.J. Merck, known as MSD outside the United States and Canada, today said that the company will voluntarily discontinue...
View Article
More Pages to Explore .....